Table 2.
Multivariate Cox Model Analyses for OS on Patients With NSCLC Receiving Neoadjuvant Chemotherapy
| Characteristics | Pathologic Stage |
MPR |
PRSC |
||||||
|---|---|---|---|---|---|---|---|---|---|
| N = 339 | HR (95% CI) | p Value | N = 339 | HR (95% CI) | p Value | N = 339 | HR (95% CI) | p Value | |
| Pathologic stage | <0.0001 | ||||||||
| 0/I (Reference) | 121 | 1.00 | |||||||
| II | 99 | 1.20 (0.81–1.76) | 0.36 | ||||||
| III | 105 | 2.07 (1.43–2.99) | <0.0001 | ||||||
| IV | 14 | 3.74 (1.93–7.24) | <0.0001 | ||||||
| MPR | <0.0001 | ||||||||
| MPR (≤10%) (reference) | 68 | 1.00 | |||||||
| No MPR (>10%) | 271 | 2.50 (1.60–3.91) | |||||||
| PRSC | 0.002 | ||||||||
| Low (reference) | 140 | 1.00 | |||||||
| Intermediate | 141 | 1.64 (1.19–2.25) | 0.01 | ||||||
| High | 58 | 3.10 (2.12–4.54) | 0.004 | ||||||
AJCC8, Union for International Cancer Control/American Joint Committee on Cancer TNM classification, eighth edition; CI, confidence interval; HR, hazard ratio; MPR, major pathologic response; OS, overall survival; PRSC, prognostic score.